Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmad Halwani

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 14, 2018
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2020
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020Neha Mehta-Shah, Steven M Horwitz, Stephen Ansell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 5, 2020
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021Steven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.
The Lancet. Oncology|August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialYoun H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Pageof 3